| CEIRR Risk Assessment Pipeline Working Groups |
Committee, Work group, Advisory group, or Task Force |
CDC, FDA |
NIAID |
Working groups to coordinate CEIRR investigators and select external partners to discuss and plan for CEIRR's pipeline and process on studying, characterizing, and responding to new influenza strains and outbreaks. The four standing working groups consist of Wild Animal Surveillance, Domestic Animal Surveillance, Phenotypic Characterization, and Phylodynamics and Computational Modeling. There are ad hoc working groups as well for specific topics, such as the Bovine H5 Outbreak working group as well. Members are mostly academic researchers funded by CEIRR, but also includes USDA, CDC, and FDA representatives, as well as NIAID staff not affiliated with CEIRR. |
| Center for Preparedness and Response (CPR) Board of Scientific Counselors (BSC) |
Committee, Work group, Advisory group, or Task Force |
CDC |
NIAID |
The Board of Scientific Counselors (BSC) is an advisory committee chartered under the Federal Advisory Committee Act. This advisory group comes together to provide advice and guidance about the public health preparedness and response activities conducted by CDC. The BSC is charged with: Advising the Secretary of Health and Human Services, the Assistant Secretary for Health, the CDC Director concerning strategies and goals for preparedness programs and research; Conducting peer-review of scientific programs; Performing secondary reviews of research proposals; and monitoring overall strategic direction and focus.The BSC is managed by the Office of Science and Public Health Practice. |
| Central Brain Tumor Registry of the United States |
Research Initiative |
CDC |
NCI |
CBTRUS is a resource for gathering and disseminating epidemiologic data on primary benign and malignant brain and other CNS tumors. Dr. Barnholtz-Sloan and her research team work with the CBTRUS team on a variety of research topics related to the epidemiology of brain tumors. |
| CEPI Interagency Meeting |
Committee, Work group, Advisory group, or Task Force |
ASPR, CDC, FDA, OGA |
NIAID |
Group convened to advise USAID in their role as CEPI funder and member of CEPI Investor Council and Board. Group meets quarterly, in advance of each CEPI board meeting, to discuss USG positions on CEPI's investment proposals that will come before the board, as well as any other issues that require collaboration. |
| CEPI-NIAID Collaboration for the development of broadly protective coronavirus vaccines |
Other |
BARDA, BARDA |
NIAID |
The purpose of the collaboration is to convene experts within and funded by the organizations to establish consensus vaccine research and development goals, coordinate resources that enable vaccine development, and to address challenges along the development path of promising BPCV candidates. |
| Cervical screening guidelines |
Resource Development |
CDC, FDA, HRSA |
NCI |
The National Cancer Institute (NCI) is generating risk estimates that inform cervical screening and management guidelines. NCI is working with CDC, HRSA, and FDA to collect study populations, conduct risk estimation, and disseminate guidelines. |
| CFAR Diversity, Equity, Inclusion Pipeline Initiative |
Research Initiative |
OASH |
FIC, NCI, NHLBI, NIA, NIAID, NIDDK, NIMH, NINR, OD/DPCPSI/OAR |
The overarching goal of the NIH-supported CFAR Diversity, Equity, and Inclusion Pipeline Initiative (CDEIPI) is to support a diverse pool of trainees who are engaged in HIV science at the high school, undergraduate, graduate (masters, doctoral or medical) and post-doctoral levels, including trainees from underrepresented racial and ethnic groups. CDEIPI seeks to develop pathways for these "CFAR Scholars" to successful careers in science and medicine. OASH provided key information and advice in the development of this initiative. |
| Characterize Emerging HIV Strains from Blood Donors and Patients |
Resource Development |
FDA |
NIAID |
This initiative will continue research to develop a well characterized, dynamic repository of diverse HIV strains for diagnostics, drug, and vaccine studies. To accomplish this, FDA and NIAID will collaborate in the work of characterizing these diverse strains and using a subset of viruses and plasma to develop globally diverse panels for evaluating performance of HIV diagnostic assays. In the era of early ART and PrEP, the performance of HIV diagnostic assays in persons on these regimens may be compromised. By developing reference materials, it will enable cross-comparison of different assays using the same reagents. |
| Chemical Hazards Emergency Medical Management (CHEMM) Working Group |
Committee, Work group, Advisory group, or Task Force |
OS |
NINDS |
The goal of CHEMM is to provide a comprehensive, user-friendly resource to help enable first responders and other healthcare providers to plan for, respond to, recover from, and mitigate the effects of mass-casualty incidents involving chemicals.https://chemm.hhs.gov/ |
| Chronic Kidney Disease Surveillance System |
Health Survey |
CDC |
NIDDK |
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) assists the Centers for Disease Control and Prevention (CDC) in its surveillance program of chronic kidney disease, including taking part in an Advisory Group to provide feedback on the program. |